Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2013-05-04 Capital/Financing Update
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
MAINBODY
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by Camp Nine, Inc. It includes offering details such as the number of shares, offering price, use of proceeds, risk factors, company description, financial condition, and management information. The document is not a report of financial results, audit, or management discussion, but rather a capital raising document describing the terms and risks of the stock offering. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length and content confirm it is the actual prospectus, not just an announcement or summary. Therefore, the correct classification is CAP with high confidence.
2013-05-04 English
MAINBODY
Interim / Quarterly Report Q2 2013
2013-05-03 English
Regulatory Filings 2013
Regulatory Filings
2013-03-25 English
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It is a correspondence related to the registration process for securities, specifically under the Securities Act of 1933. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication about the filing process rather than the filing itself. The document length is short (1533 characters), and it is clearly a formal request letter, not a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with the SEC that do not fit other categories.
2013-03-19 English
MAINBODY
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is related to an initial public offering (IPO) of common stock by Camp Nine, Inc. The document includes a prospectus with detailed information about the offering, risk factors, business description, financial statements, and other disclosures typical of a registration statement for securities offerings. This type of filing is a capital/financing update as it pertains to the company's fundraising activities and securities registration. It is not an annual report, earnings release, or other types of filings listed. Therefore, the correct classification is Capital/Financing Update (CAP).
2013-03-07 English
Regulatory Filings 2013
Regulatory Filings
2013-03-01 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.